The Boeing Company

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Boeing Slips 3.2% in 3 Months: Is a Better Entry Point Ahead? - tradingview.com

AI-generated analysis

πŸ“‰ BA shares slipped 3.2% over the past three months, slightly outperforming the Zacks Aerospace-Defense industry which declined 3.8%.

πŸ’° Boeing's Defense, Space & Security (BDS) segment revenues grew 13% year-over-year to $7.48 billion in Q2 2026.

πŸ“¦ The BDS division ended the quarter with an $85 billion backlog, with 27% of orders tied to customers outside the United States.

🀝 Boeing completed the sale of its 50% stake in HRL Laboratories to IBM to focus capital on core aerospace and defense businesses.

πŸš€ New seven-year framework agreements for Standard Missile-3 (SM-3) provide long-term visibility and growth opportunities for the BDS segment.

⏳ The 777X program is running seven years late with an expected entry-into-service date pushed to 2027 due to FAA scrutiny and design changes.

πŸ’Έ Boeing recorded $2.78 billion in aircraft order cancellations during the six months ended June 30, 2026, primarily affecting the 737 line.

πŸ“ˆ Analyst consensus estimates indicate a year-over-year improvement of 91.82% for Boeing's 2026 earnings per share (EPS).

πŸ’§ Boeing maintains a healthy liquidity position with a current ratio of 1.14, compared to the industry average of 1.10.

πŸ“‰ Valuation-wise, Boeing trades at a forward 12-month price-to-sales ratio of 1.55X, which is a discount to the industry average of 2.36X.

⚠️ Ongoing trade tensions between the United States and China pose a risk that could delay deliveries and hurt revenues.

πŸ“‰ The company has an average negative earnings surprise of 113.46% over the trailing four quarters, having beaten estimates in only one quarter.

Bullish Signals
  • Boeing's Defense, Space & Security (BDS) segment revenues increased 13% year-over-year to $7.48 billion in Q2 2026.
  • The BDS division ended the quarter with a robust $85 billion backlog, providing strong revenue visibility.
  • Boeing completed the sale of its stake in HRL Laboratories to IBM, allowing a strategic refocus on core aerospace operations.
  • New seven-year framework agreements for Standard Missile-3 (SM-3) provide long-term demand visibility and growth opportunities.
  • Analyst consensus estimates project a significant year-over-year improvement of 91.82% for Boeing's 2026 earnings per share.
  • Boeing maintains a healthy liquidity position with a current ratio of 1.14, exceeding the industry average.
  • The company trades at a forward price-to-sales ratio of 1.55X, offering a valuation discount to the industry average of 2.36X.
Risk Factors
  • Slow production, delayed deliveries, and ongoing inspections are turning customers away from Boeing's commercial airplanes.
  • The 777X program is running seven years late with an expected entry-into-service date pushed to 2027.
  • Delays in the 777X program have resulted in significant cost overruns and rigorous FAA scrutiny.
  • Boeing recorded $2.78 billion in aircraft order cancellations during the six months ended June 30, 2026.
  • The company has an average negative earnings surprise of 113.46% over the trailing four quarters.
Full Analysis
Boeing's (BA) shares have declined 3.2% over the past three months, underperforming slightly relative to the broader aerospace-defense industry which fell 3.8%. Despite this price dip, the company maintains a strong position as one of the largest U.S. commercial aircraft manufacturers with an optimistic outlook for its defense and space business segment. The Defense, Space & Security (BDS) division reported robust financial performance in the second quarter of 2026, with revenues increasing 13% year-over-year to $7.48 billion. This growth was driven by higher volumes in classified programs, missiles, weapons, and KC-46A activity. The segment also booked $7 billion in orders and ended the quarter with a substantial $85 billion backlog, 27% of which is tied to international customers. Strategic initiatives include the recent sale of Boeing's stake in HRL Laboratories to IBM, allowing the company to refocus resources on core aerospace operations. Additionally, new seven-year framework agreements for Standard Missile-3 (SM-3) provide long-term visibility into demand for critical missile-defense components, supporting production increases for avionics and ejector assemblies. However, significant challenges persist in Boeing's commercial aviation division due to slow production, delayed deliveries, and ongoing FAA inspections. The 777X program is running seven years late with an expected entry-into-service date of 2027, accompanied by significant cost overruns. Furthermore, the company faced $2.78 billion in aircraft order cancellations during the six months ended June 30, 2026, primarily related to the 737 aircraft.